| Literature DB >> 24736285 |
Nikki McCaffrey1, Pawel Skuza2, Katrina Breaden3, Simon Eckermann4, Janet Hardy5, Sheila Oaten6, Michael Briffa7, David Currow3.
Abstract
INTRODUCTION: The ability of patients to finalise their affairs at the end of life is an often neglected aspect of quality of life (QOL) measurement in palliative care effectiveness research despite compelling evidence of the high value patients place on this domain.Entities:
Mesh:
Year: 2014 PMID: 24736285 PMCID: PMC3988060 DOI: 10.1371/journal.pone.0094316
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
The end-of-life patient-reported outcome measure.
| Not at all | A little bit | Some-what | Quite a bit | Very much | |
| I am able to manage my personal and financial affairs as I would wish……… | 0 | 1 | 2 | 3 | 4 |
Figure 1Scripted probes for the cognitive interview.
Key eligibility criteria in the ketamine trial [24].
| Inclusion criteria | Exclusion criteria |
| Age >18 years | Previous ketamine use in the last six months |
| Pain related to cancer or its treatment | Unstable pain, or undergoing active treatment to reduce pain (surgery, chemotherapy, radiotherapy) |
| Moderate to severe pain | Medical history places patient at risk of known adverse reactions |
| Patients with either primarily nociceptive | Recent monoamine oxidase inhibitors |
| Stable background opioid dose | Previous recreational drug history |
| Stable co-analgesics during the study period |
Leeds Assessment of Neuropathic Symptoms and Signs score (LANSS) <12;
LANSS score >12.
Qualitative study participant characteristics.
| Characteristic | Total number (N = 9) |
|
| |
| Age in years, mean (range) | 69 (47–88) |
| Gender, M/F | 3/6 |
| English is the usual language spoken at home, n | 9 |
| Primary caregiver identified, n | 7 |
| Highest education level achieved, n | |
| Up to year 9 | 2 |
| Years 10–12 | 4 |
| Completed university or TAFE | 2 |
| Postgraduate | 1 |
|
| |
| Main life limiting illness, n | |
| Advanced cancer | 4 |
| Motor Neurone Disease | 3 |
| Heart Failure | 1 |
| COPD | 1 |
| Time since diagnosis (months), median (IQR) | 12 (11) |
| min-max | 1–120 |
| MMSE score, mean (range) | 28 (28–30) |
| AKPS score, n | |
| 80 | 2 |
| 70 | 1 |
| 60 | 2 |
| 50 | 3 |
| 40 | 1 |
AKPS = Australian-modified Karnofsky Performance Status; COPD = chronic obstructive pulmonary disease; F = female; IQR = inter-quartile range; M = male; MMSE = Mini-Mental State Examination; SD = standard deviation; TAFE = Technical and Further Education.
Figure 2Links between key themes identified from the cognitive interviews.
Ketamine sample baseline characteristics.
| Characteristic | Number of cases (N = 185) | |
| Age (years), mean (SD) | 63.6 (11.9) | 182 |
| Gender, male (%) | 103 (56.6) | 182 |
| Site of cancer diagnosis (n = 183), n (%) | ||
| Lung | 40 (21.9) | |
| Prostate | 24 (13.1) | |
| Colorectal | 22 (12.0) | |
| Breast | 17 (9.3) | |
| Gynaecologic | 11 (6.0) | |
| Pancreas | 10 (5.5) | |
| Bone/soft tissue | 7 (3.8) | |
| Other | 52 (28.4) | |
| EOLPRO, median (IQR) | 3 (2) | 137 |
| AKPS, median (IQR) | 60 (10) | 182 |
| EORTC QLQ-C15-PAL Question 10, median (IQR) | 2 (2) | 160 |
| BPI, mean (SD) | 5.3 (1.4) | 181 |
the median and interquartile range are reported given the ordinal nature of the data;
the EOLPRO was introduced 5 months after study initiation;
the distribution of the BPI was approximately normal, hence the mean and standard deviation are reported; AKPS = Australian-modified Karnofsky Performance Status; BPI = Brief Pain Inventory Scale; EOLPRO = end of life patient reported outcome; IQR = interquartile range; SD = standard deviation.
Proportion of missing values for key variables in the ketamine sample data.
| Variable | Missing | Available | ||
| Baseline n (%) | Follow up n (%) | Baseline n (%) | Follow up n (%) | |
| EOLPRO | 48 (25.9) | 81 (43.8) | 137 (74.1) | 104 (56.2) |
| EORTC QLQ-C15-PAL QOL | 32 (17.3) | 73 (39.5) | 153 (82.7) | 112 (60.5) |
| EORTC QLQ-C15-PAL Qu 10 | 25 (13.5) | 71 (38.4) | 160 (86.5) | 114 (61.6) |
| AKPS | 3 (1.6) | 8 (4.3) | 182 (98.4) | 177 (95.7) |
| BPI score | 4 (2.2) | 13 (7.0) | 181 (97.8) | 172 (93.0) |
AKPS = Australian-modified Karnofsky Performance Status; BPI = Brief Pain Inventory; EOLPRO = end of life patient reported outcome; MMSE = Mini-Mental State Examination; QOL = quality of life.
Summary of the correlations between EOLPRO scores and other established scales and clinical measures.
| Measure | Spearman’s correlation coefficient (95% CI) | Effect size | p-value |
|
| |||
| AKPS (n = 137) | 0.41 (0.26, 0.54) | moderate | <0.01 |
| BPI (n = 137) | 0.10 (−0.08, 0.26) | very weak | 0.25 |
| Proximity to death (n = 28) | 0.30 (−0.09, 0.59) | moderate | 0.13 |
|
| |||
| EORTC QLQ-C15-PAL Question 10 (n = 127) | 0.02 (−0.15, 0.19) | negligible | 0.85 |
correlations were considered significant when the probability of making a type I error was less than 0.8% to allow for multiple testing;
statistically significant result; AKPS = Australian-modified Karnofsky Performance Status; BPI = Brief Pain Inventory; CI = bootstrap BCa confidence intervals.
Post-treatment EOLPRO scores and responder status cross tabulation.
| Post-treatment EOLPRO scores n (%) | ||||||
| 0: not at all | 1: a little bit | 2: somewhat | 3: quite a bit | 4: very much | Total | |
| Responder | 3 (8.6) | 4 (11.4) | 8 (22.9) | 7 (20.0) | 13 (37.1) | 35 |
| Non-responder | 8 (11.6) | 6 (8.7) | 15 (21.7) | 15 (21.7) | 25 (36.2) | 69 |
| Total | 11 (10.6) | 10 (9.6) | 23 (22.1) | 22 (21.2) | 38 (36.5) | 104 |